A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
OBJECTIVE
Nimotuzumab is a humanized monoclonal antibody which inhibits the ligand-dependent activation of epidermal growth factor receptor (EGFR). We conducted a phase I trial to assess the pharmacodynamic (PD) effects of escalating doses of nimotuzumab administered alone in patients with advanced solid cancers patients.


METHODS
Patients were treated with escalating doses of weekly intravenous nimotuzumab at doses ranging between 100 and 800 mg. Tumor and skin biopsies were done before start of treatment and repeated 3 weeks after to assess immunohistochemical expression of EGFR and its downstream components.


RESULTS
Seventeen patients were enrolled, including 1 patient never treated. Although 1 dose-limiting-toxicity (DLT) was observed at 100 mg (grade 3 fatigue), nimotuzumab dose was escalated to 800 mg with no other DLT. No grade 4 toxicity was observed. Only 3 patients developed a grade 1 acneiform rash (18.7%). One patient achieved a partial response (6.2%) and 8 patients had stable disease (50.0%). The median TTP was 2.4 months. No significant changes in EGFR, AKT, ERK and Ki67 immuno-stainings were observed between pre- and on-treatment tumor or skin biopsies.


CONCLUSIONS
Nimotuzumab could be safety administered up to 800 mg with manageable toxicity. No relationships were found between pharmacodynamic effects on EGFR downstream signaling pathways and drug efficacy or toxicity.
You
Benoit
B
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
Brade
Anthony
A
Magalhaes
Joao M
JM
Siu
Lillian L
LL
Oza
Amit
A
Lovell
Sonya
S
Wang
Lisa
L
Hedley
David W
DW
Nicacio
Leonardo V
LV
Chen
Eric X
EX
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008024:Ligands; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology*; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D008024:Ligands; C501466:nimotuzumab; D066246:ErbB Receptors
Ai Zheng. 2007 Aug;26(8):874-9
17697551
Nucl Med Commun. 2002 Dec;23(12):1155-64
12464779
Cancer Treat Rev. 2009 Jun;35(4):354-63
19269105
Nucl Med Commun. 2005 Dec;26(12):1049-57
16264350
J Histochem Cytochem. 2010 Mar;58(3):237-46
19901271
Am J Pathol. 2003 Nov;163(5):1687-98
14578166
Cancer Biol Ther. 2006 Apr;5(4):375-9
16575203
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Cancer Biol Ther. 2008 Mar;7(3):333-9
18094616
Cancer Res. 2009 Jul 15;69(14):5851-9
19584289
Clin Cancer Res. 2006 Nov 1;12(21):6517-22
17065274
Clin Cancer Res. 2000 Feb;6(2):701-8
10690556
J Clin Oncol. 2003 Jul 15;21(14):2787-99
12860957
Diagn Pathol. 2007 Feb 27;2:8
17326824
J Immunother. 2003 Mar-Apr;26(2):139-48
12616105
J Clin Oncol. 2009 Jun 10;27(17):2751-7
19332731
J Clin Oncol. 2004 May 1;22(9):1646-54
15117987
Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):197-201
17649636
Cancer Control. 2005 Apr;12(2):105-10
15855893
Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5
20557849
Int J Cancer. 2002 Oct 20;101(6):567-75
12237899
Clin Cancer Res. 2007 Feb 1;13(3):986-93
17289894
Acta Oncol. 2008;47(1):9-19
18097777